References

Parkinson's disease

10.1016/s0140-6736(21)00218-x · 2021 · External reference

Advances in diagnosis, classification, and management of pain in Parkinson's disease

10.1016/s1474-4422(25)00033-x · 2025 · External reference

Pathogenesis of Parkinson's Disease

10.1016/j.ncl.2024.12.003 · 2025 · External reference

Exercise and gait/movement analyses in treatment and diagnosis of Parkinson's Disease

10.1016/j.arr.2023.102147 · 2024 · External reference

Nanomedicine in the Face of Parkinson's Disease: From Drug Delivery Systems to Nanozymes

10.3390/cells11213445 · 2022 · External reference

Nanomedicine for Neurodegenerative Disorders: Focus on Alzheimer's and Parkinson's Diseases

10.3390/ijms22169082 · 2021 · External reference

Blood-brain barrier alterations and their impact on Parkinson's disease pathogenesis and therapy

10.1186/s40035-024-00430-z · 2024 · External reference

Blood-brain barrier biomarkers

10.1016/bs.acc.2024.04.004 · 2024 · External reference

Blood-Brain Barrier (BBB) Dysfunction in CNS Diseases: Paying Attention to Pericytes

10.1111/cns.70422 · 2025 · External reference

An Engineered Bionic Nanoparticle Sponge as a Cytokine Trap and Reactive Oxygen Species Scavenger to Relieve Disc Degeneration and Discogenic Pain

10.1021/acsnano.3c08097 · 2024 · External reference

Targeted delivery of berberine using bionic nanomaterials for Atherosclerosis therapy

10.1016/j.biopha.2024.117135 · 2024 · External reference

Targeted ROS Scavenging for Disease Therapies Using Nanomaterials

10.1002/adma.202504435 · 2025 · External reference

Biomimetic Nanoparticles Enhance Recovery of Movement Disorders in Parkinson's Disease by Improving Microglial Mitochondrial Homeostasis and Suppressing Neuroinflammation

10.1021/acsami.4c22181 · 2025 · External reference

Platelet-Membrane-Coated Polydopamine Nanoparticles for Neuroprotection by Reducing Oxidative Stress and Repairing Damaged Vessels in Intracerebral Hemorrhage

10.1002/adhm.202300797 · 2023 · External reference

Lipid nanoparticle-mediated drug delivery to the brain

10.1016/j.addr.2023.114861 · 2023 · External reference

Efficient Delivery of Lomitapide using Hybrid Membrane-Coated Tetrahedral DNA Nanostructures for Glioblastoma Therapy

10.1002/adma.202311760 · 2024 · External reference

Recent Advances in Inorganic Chiral Nanomaterials

10.1002/adma.202005506 · 2021 · External reference

Nano-fiber/net artificial bionic dura mater promotes neural stem cell differentiating by time sequence external-oral administration to repair spinal cord injury

10.7150/thno.102584 · 2025 · External reference

Design and synthesis of bioinspired nanomaterials for biomedical application

10.1002/wnan.1914 · 2024 · External reference

Bioinspired soft nanovesicles for site-selective cancer imaging and targeted therapies

10.1002/wnan.1792 · 2022 · External reference

Nano-Engineering Strategies for Tumor-Specific Therapy

10.1002/cmdc.202300647 · 2024 · External reference

Advances in Drug Delivery Systems Based on Red Blood Cells and Their Membrane-Derived Nanoparticles

10.1021/acsnano.2c11965 · 2023 · External reference

Hierarchically structured bioinspired nanocomposites

10.1038/s41563-022-01384-1 · 2023 · External reference

Bioinspired Screening of Anti-Adhesion Peptides against Blood Proteins for Intravenous Delivery of Nanomaterials

10.1021/acs.nanolett.2c02243 · 2022 · External reference

Antimicrobial and anti-biofilm activities of bio-inspired nanomaterials for wound healing applications

10.1016/j.drudis.2023.103673 · 2023 · External reference

Neuromorphic Floating-Gate Memory Based on 2D Materials

10.34133/cbsystems.0256 · 2025 · External reference

Platelets and diseases: signal transduction and advances in targeted therapy

10.1038/s41392-025-02198-8 · 2025 · External reference

Platelets: A new therapeutic target for neurological diseases

10.1016/j.arr.2025.102874 · 2025 · External reference

Platelet and Megakaryocyte Roles in Innate and Adaptive Immunity

10.1161/circresaha.121.319821 · 2022 · External reference

Beyond Hemostasis: Platelet Innate Immune Interactions and Thromboinflammation

10.3390/ijms23073868 · 2022 · External reference

Cell membrane-camouflaged nanomedicines for enhanced thrombolysis and blood-brain barrier penetration in ischemic stroke therapy

10.1016/j.ijpx.2025.100404 · 2025 · External reference

Recent advances of engineering cell membranes for nanomedicine delivery across the blood-brain barrier

10.1186/s12951-025-03572-y · 2025 · External reference

Blood-Brain Barrier-Penetrating and Lesion-Targeting Nanoplatforms Inspired by the Pathophysiological Features for Synergistic Ischemic Stroke Therapy

10.1002/adma.202312897 · 2024 · External reference

Characterization and Chromatographic Isolation of Platelet Extracellular Vesicles from Human Platelet Lysates for Applications in Neuroregenerative Medicine

10.1021/acsbiomaterials.1c01226 · 2021 · External reference

Neurotrophic Factors in Parkinson's Disease: Clinical Trials, Open Challenges and Nanoparticle-Mediated Delivery to the Brain

10.3389/fncel.2021.682597 · 2021 · External reference

Multifunctional magnetoliposomes as drug delivery vehicles for the potential treatment of Parkinson's disease

10.3389/fbioe.2023.1181842 · 2023 · External reference

Microglia rescue neurons from aggregate-induced neuronal dysfunction and death through tunneling nanotubes

10.1016/j.neuron.2024.06.029 · 2024 · External reference

Characterizing and targeting glioblastoma neuron-tumor networks with retrograde tracing

10.1016/j.cell.2024.11.002 · 2025 · External reference

Aptamer functionalized cell membrane for brain and nerve cell sensing with high sensitivity and stability

10.1016/j.bios.2023.115149 · 2023 · External reference

Endogenous cell membrane interactome mapping for the GLP-1 receptor in different cell types

10.1038/s41589-024-01714-1 · 2025 · External reference

Adipo-glial signaling mediates metabolic adaptation in peripheral nerve regeneration

10.1016/j.cmet.2023.10.017 · 2023 · External reference

Multiscale NIR-II Imaging-Guided Brain-Targeted Drug Delivery Using Engineered Cell Membrane Nanoformulation for Alzheimer's Disease Therapy

10.1021/acsnano.2c12840 · 2023 · External reference

Blood-brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system

10.1038/s41563-024-02114-5 · 2025 · External reference

New Blood-Brain Barrier Models Using Primary Parkinson's Disease Rat Brain Endothelial Cells and Astrocytes for the Development of Central Nervous System Drug Delivery Systems

10.1021/acschemneuro.1c00118 · 2021 · External reference

Microfluidics-enabled mesenchymal stem cell derived Neuron like cell membrane coated nanoparticles inhibit inflammation and apoptosis for Parkinson's Disease

10.1186/s12951-024-02587-1 · 2024 · External reference

Liposome composition in drug delivery design, synthesis, characterization, and clinical application

10.1016/j.addr.2021.113851 · 2021 · External reference

Biomimetic nanoparticles for targeted therapy of liver disease

10.1039/d5pm00044k · 2025 · External reference

Targeting mRNA delivery using bio-inspired hybrid cell membrane-incorporated liposomes: a novel strategy for cancer therapy

10.1186/s40364-026-00953-9 · 2026 · External reference

Tumor cell membrane-camouflaged biomimetic liposomes for targeted delivery of phytosphingosine with enhanced anti-lung cancer activity

10.1016/j.colsurfb.2026.115894 · 2026 · External reference

A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives

10.3390/molecules27041372 · 2022 · External reference

Advanced liposome and polymersome-based drug delivery systems: Considerations for physicochemical properties, targeting strategies and stimuli-sensitive approaches

10.1016/j.cis.2023.102930 · 2023 · External reference

Astrocytes and microglia-targeted Danshensu liposomes enhance the therapeutic effects on cerebral ischemia-reperfusion injury

10.1016/j.jconrel.2023.11.002 · 2023 · External reference

Tailoring the adjuvanticity of lipid nanoparticles by PEG lipid ratio and phospholipid modifications

10.1038/s41565-025-01958-5 · 2025 · External reference

Engineering membrane architecture for biotechnological applications

10.1016/j.biotechadv.2023.108118 · 2023 · External reference

Engineered exosomes with a photoinducible protein delivery system enable CRISPR-Cas-based epigenome editing in Alzheimer's disease

10.1126/scitranslmed.adi4830 · 2024 · External reference

Engineered Enucleated Mesenchymal Stem Cells Regulating Immune Microenvironment and Promoting Wound Healing

10.1002/adma.202412253 · 2024 · External reference

Engineered Exosome for Drug Delivery: Recent Development and Clinical Applications

10.2147/ijn.s444582 · 2023 · External reference

CAR Macrophages Engineered In Vivo for Attenuating Myocardial Ischemia-Reperfusion Injury

10.1161/circresaha.125.326716 · 2025 · External reference

Brain-Targeted Liposomes Loaded with Monoclonal Antibodies Reduce Alpha-Synuclein Aggregation and Improve Behavioral Symptoms in Parkinson's Disease

10.1002/adma.202304654 · 2023 · External reference

Next-generation lipid nanocarriers for Parkinson's therapy: nose-to-brain innovations and clinical prospects

10.1039/d5nr03373j · 2025 · External reference

Targeting dysregulated lipid metabolism for the treatment of Alzheimer's disease and Parkinson's disease: Current advancements and future prospects

10.1016/j.nbd.2024.106505 · 2024 · External reference

Recent advances in cell membrane-based biomimetic delivery systems for Parkinson's disease: Perspectives and challenges

10.1016/j.ajps.2025.101060 · 2025 · External reference

Biomimetic and cell-based nanocarriers - New strategies for brain tumor targeting

10.1016/j.jconrel.2021.07.047 · 2021 · External reference

Inspiring biomimetic system based on red blood cell membrane vesicles for effective curcumin loading and release

10.1016/j.ijpharm.2021.121419 · 2022 · External reference

Cell Membrane- and Vesicle-Based Bionic Nanodrugs: Applications in Central Nervous System Diseases and Exploration of Nasal-Cerebral Delivery

10.3390/gels11110846 · 2025 · External reference

Ginkgolide A improves the pleiotropic function and reinforces the neuroprotective effects by mesenchymal stem cell-derived exosomes in 6-OHDA-induced cell model of Parkinson's disease

10.18632/aging.204526 · 2023 · External reference

Cutting-Edge Progress in the Acquisition, Modification and Therapeutic Applications of Exosomes for Drug Delivery

10.2147/ijn.s516840 · 2025 · External reference

Hybrid Membrane-Coated Nanoparticles for Precise Targeting and Synergistic Therapy in Alzheimer's Disease

10.1002/advs.202306675 · 2024 · External reference

From neuroinflammation to immune reprogramming: Nanozyme-Integrated nanoplatforms for neuroimmune modulation in Parkinson's disease

10.1016/j.mtbio.2026.103569 · 2026 · External reference

Exosome mimetic nanoparticles for siRNA based targeting of α-synuclein and neuroinflammation in Parkinson's disease

10.1093/jpp/rgag052 · 2026 · External reference

Enhanced neuroprotection in Parkinson's disease by neutrophil-biomimetic nanovesicles through autophagy inhibition and apoptosis antagonism

10.1016/j.cej.2025.166832 · 2025 · External reference

Exosomes-encapsulated biomimetic polydopamine carbon dots with dual-targeting effect alleviate motor and non-motor symptoms of Parkinson's disease via anti-neuroinflammation

10.1016/j.ijbiomac.2025.139724 · 2025 · External reference

Delivery of Biomimetic Liposomes via Meningeal Lymphatic Vessels Route for Targeted Therapy of Parkinson's Disease

10.34133/research.0030 · 2023 · External reference

Platelet concentrate-derived extracellular vesicles promote adult hippocampal neurogenesis

10.1016/j.biomaterials.2025.123838 · 2026 · External reference

Nano Lipid Carriers as a Promising Drug Delivery Carrier for Neurodegenerative Disorders - An Overview of Recent Advances

10.2174/1872208317666230320164219 · 2024 · External reference

Targeting lipid nanoparticles to the blood-brain barrier to ameliorate acute ischemic stroke

10.1016/j.ymthe.2024.03.004 · 2024 · External reference

Engineered Selenium/Human Serum Albumin Nanoparticles for Efficient Targeted Treatment of Parkinson's Disease via Oral Gavage

10.1021/acsnano.3c05011 · 2023 · External reference

Ameliorating Mitochondrial Dysfunction of Neurons by Biomimetic Targeting Nanoparticles Mediated Mitochondrial Biogenesis to Boost the Therapy of Parkinson's Disease

10.1002/advs.202300758 · 2023 · External reference

Engineered Biomimetic Nanorobots Orchestrate Targeted Nose-to-Brain Delivery to Resolve Neuron-Glia Entanglement against Parkinson's Disease

10.1002/smll.202513394 · 2026 · External reference

Nanozyme-integrated curcumin exosome biomimetic nanosystems traverse the blood–brain barrier for anti-inflammatory Parkinson’s therapy

10.1016/j.matdes.2026.115899 · 2026 · External reference

Development of Multifunctional Nanoparticles for Therapy and/or Diagnosis

10.3390/nano12142321 · 2022 · External reference

Ferritin: A Multifunctional Nanoplatform for Biological Detection, Imaging Diagnosis, and Drug Delivery

10.1021/acs.accounts.1c00267 · 2021 · External reference

Multifunctional Magnetic Nanoparticles for Targeted Drug Delivery Against Cancer: A Review of Mechanisms, Applications, Consequences, Limitations, and Tailoring Strategies

10.1007/s10439-025-03712-3 · 2025 · External reference

Nanostars Carrying Multifunctional Neurotrophic Dendrimers Protect Neurons in Preclinical In Vitro Models of Neurodegenerative Disorders

10.1021/acsami.2c14220 · 2022 · External reference

Multifunctional Nanoprobe for the Delivery of Therapeutic siRNA and Real-Time Molecular Imaging of Parkinson's Disease Biomarkers

10.1021/acsami.0c22112 · 2021 · External reference

Biomimetic platelet membrane-coated nanoparticles for targeted therapy

10.1016/j.ejpb.2022.01.004 · 2022 · External reference

Neural Cell Membrane-Coated Nanoparticles for Targeted and Enhanced Uptake by Central Nervous System Cells

10.1021/acsami.1c16543 · 2021 · External reference

Preparation and Pharmacokinetics of Brain-Targeted Nanoliposome Loaded with Rutin

10.3390/ijms252111404 · 2024 · External reference

Brain-targeted drug delivery by in vivo functionalized liposome with stable D-peptide ligand

10.1016/j.jconrel.2024.07.014 · 2024 · External reference

Management of Brain Cancer and Neurodegenerative Disorders with Polymer-Based Nanoparticles as a Biocompatible Platform

10.3390/molecules28020841 · 2023 · External reference

Exosome Enveloped by Nano Lipid Particle a New Model for Signal Transducer and Activator of Transcription 3 Silencer Ribonucleic Acid Delivery System to a Glioblastoma Mice Model

10.3390/cancers17101648 · 2025 · External reference

Engineered Bacterial Outer Membrane Vesicles-Based Doxorubicin and CD47-siRNA Co-Delivery Nanoplatform Overcomes Immune Resistance to Potentiate the Immunotherapy of Glioblastoma

10.1002/adma.202418053 · 2025 · External reference

The blood-brain barrier

10.1016/j.cub.2025.06.061 · 2025 · External reference

A study of bidirectional control of Parkinson’s beta oscillations by basal ganglia

10.1016/j.chaos.2025.116267 · 2025 · External reference

Sepsis-Associated Encephalopathy and Blood-Brain Barrier Dysfunction

10.1007/s10753-021-01501-3 · 2021 · External reference

Brain Endothelial Cells in Blood-Brain Barrier Regulation and Neurological Therapy

10.3390/ijms26125843 · 2025 · External reference

Human iPS-derived blood-brain barrier model exhibiting enhanced barrier properties empowered by engineered basement membrane

10.1016/j.biomaterials.2022.121983 · 2023 · External reference

Regulation of blood-brain barrier integrity by Dmp1-expressing astrocytes through mitochondrial transfer

10.1126/sciadv.adk2913 · 2024 · External reference

Blood-Brain Barrier Dysfunction and Astrocyte Senescence as Reciprocal Drivers of Neuropathology in Aging

10.3390/ijms23116217 · 2022 · External reference

The Blood-Brain Barrier in Health and Disease

10.3390/ijms24119261 · 2023 · External reference

Blood-brain barrier transporters: An overview of function, dysfunction in Alzheimer's disease and strategies for treatment

10.1016/j.bbadis.2023.166967 · 2024 · External reference

Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis

10.1016/j.medj.2022.09.007 · 2022 · External reference

Salidroside promotes pro-angiogenesis and repair of blood brain barrier via Notch/ITGB1 signal path in CSVD Model

10.1016/j.jare.2024.02.019 · 2025 · External reference

Schiff Base-Wrapped Co, Zn-Based Clusters with Hierarchical Chiral Structures for Therapeutic Application in Parkinson's Disease

10.1021/acs.inorgchem.6c00360 · 2026 · External reference

Multimodal bifurcation control of parkinsonian beta oscillations by pedunculopontine nucleus pathways: A unified computational framework revealing dynamic therapeutic targets

10.3934/era.2026054 · 2026 · External reference

Modeling neurodegeneration and neuroinflammation in Parkinson's Disease: Animal-based strategies

10.1016/bs.mcb.2025.02.006 · 2025 · External reference

IGFBP5 Promotes Neuronal Apoptosis in a 6-OHDA-Toxicant Model of Parkinson's Disease by Inhibiting the Sonic Hedgehog Signaling Pathway

10.1159/000538467 · 2024 · External reference

Generation of Mitochondrial Toxin Rodent Models of Parkinson's Disease Using 6-OHDA, MPTP, and Rotenone

10.1007/978-1-0716-1495-2_10 · 2021 · External reference

Unresolved reference

2025 · External reference

Unresolved reference

2026 · External reference

Bilateral intranigral α-synuclein seeding in A53T transgenic mice drives early Parkinsonism and concurrent gut dysbiosis

10.1016/j.bbrc.2026.154244 · 2026 · External reference

Intranigral injection of alpha-synuclein pre-formed fibrils leads to BBB compromise and bilateral dopaminergic neurodegeneration in A53T alpha-synuclein transgenic mice

10.1186/s13064-026-00286-1 · 2026 · External reference

Spatial lipidomics reveals brain region-specific changes of sulfatides in an experimental MPTP Parkinson's disease primate model

10.1038/s41531-023-00558-1 · 2023 · External reference

Drug discovery and development for Parkinson's disease: are preclinical models good enough?

10.3389/fnagi.2025.1692592 · 2025 · External reference

Targeted Delivery of Mesenchymal Stem Cell-Derived Bioinspired Exosome-Mimetic Nanovesicles with Platelet Membrane Fusion for Atherosclerotic Treatment

10.2147/ijn.s452824 · 2024 · External reference

Fusogenic lipid nanoparticles for rapid delivery of large therapeutic molecules to exosomes

10.1038/s41467-025-59489-5 · 2025 · External reference

Promoting Cell Fusion by Polyvalent DNA Ligands

10.1021/acs.nanolett.2c00216 · 2022 · External reference

A Biomimetic Drug Delivery System by Integrating Grapefruit Extracellular Vesicles and Doxorubicin-Loaded Heparin-Based Nanoparticles for Glioma Therapy

10.1021/acs.nanolett.0c04753 · 2021 · External reference

DH5α Outer Membrane-Coated Biomimetic Nanocapsules Deliver Drugs to Brain Metastases but not Normal Brain Cells via Targeting GRP94

10.1002/smll.202300403 · 2023 · External reference

Sortilin regulates blood-brain barrier integrity

10.1111/febs.16225 · 2022 · External reference

Immune Exosomes Loading Self-Assembled Nanomicelles Traverse the Blood-Brain Barrier for Chemo-immunotherapy against Glioblastoma

10.1021/acsnano.2c10219 · 2023 · External reference

Anti-Parkinsonian Therapy: Strategies for Crossing the Blood-Brain Barrier and Nano-Biological Effects of Nanomaterials

10.1007/s40820-022-00847-z · 2022 · External reference

Peptide-Functionalized Lipid Nanoparticles for Targeted Systemic mRNA Delivery to the Brain

10.1021/acs.nanolett.4c05186 · 2025 · External reference

Inorganic nanoparticles and blood-brain barrier modulation: Advancing targeted neurological therapies

10.1016/j.ejmech.2025.117357 · 2025 · External reference

Targeted Nanoparticles for Drug Delivery Across the Blood-Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review

10.1007/s12035-025-05417-z · 2025 · External reference

NIR-Assisted MgO-Based Polydopamine Nanoparticles for Targeted Treatment of Parkinson's Disease through the Blood-Brain Barrier

10.1002/adhm.202201655 · 2022 · External reference

Living Cells and Cell-Derived Vesicles: A Trojan Horse Technique for Brain Delivery

10.3390/pharmaceutics15041257 · 2023 · External reference

Biomimetic membrane-coated metal nanoplatforms for enhanced BBB penetration and targeted glioblastoma therapy

10.1016/j.ijpx.2026.100612 · 2026 · External reference

Overcoming the blood–brain barrier: nanomedicine strategies for targeted delivery and multimodal therapy in Alzheimer's disease

10.1080/10717544.2026.2645830 · 2026 · External reference

Bioinspired lipid-polysaccharide modified hybrid nanoparticles as a brain-targeted highly loaded carrier for a hydrophilic drug

10.1016/j.ijbiomac.2020.09.170 · 2020 · External reference

Glycocalyx-Mimicking Nanoparticles with Differential Organ Selectivity for Drug Delivery and Therapy

10.1002/adma.202311283 · 2024 · External reference

Fusogenic lipid nanocarriers: Nature-inspired design for advanced drug delivery systems

10.1016/j.cis.2025.103667 · 2025 · External reference

MFSD2A: a molecular nexus linking blood-brain barrier, lipid metabolism, and ischemia-reperfusion injury

10.1186/s11658-025-00828-1 · 2025 · External reference

Lipid Nanoparticles: Versatile Drug Delivery Vehicles for Traversing the Blood Brain Barrier to Treat Brain Cancer

10.1002/adfm.202404234 · 2024 · External reference

Engineered biomembrane-derived nanoparticles for nanoscale theranostics

10.7150/thno.76894 · 2023 · External reference

Receptor-mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria

10.3389/fddev.2024.1360302 · 2024 · External reference

A pH-sensitive binding modality allows successful transferrin receptor-mediated transcytosis of a bivalent antibody across brain barriers

10.1080/19420862.2025.2563758 · 2025 · External reference

Bifunctional Molecules That Induce Both Targeted Degradation and Transcytosis of Extracellular Proteins in Brain Cells

10.1021/jacs.3c13320 · 2024 · External reference

Angiopep-2-decorated bacterial outer membrane vesicles penetrate the blood-brain barrier for glioblastoma chemo-immunotherapy

10.1080/10717544.2026.2660007 · 2026 · External reference

Pcpe2, a Novel Extracellular Matrix Protein, Regulates Adipocyte SR-BI-Mediated High-Density Lipoprotein Uptake

10.1161/atvbaha.121.316615 · 2021 · External reference

tLyp-1: A peptide suitable to target NRP-1 receptor

10.1016/j.bioorg.2022.106200 · 2023 · External reference

Platelet membrane-coated nanoparticles inhibit platelet activation and neutrophil extracellular traps formation in acute lung injury

10.1186/s12967-025-06649-2 · 2025 · External reference

Engineered Cell Membrane-Coated Nanoparticles: New Strategies in Glioma Targeted Therapy and Immune Modulation

10.1002/adhm.202400514 · 2024 · External reference

Hybrid membrane-coated nanosuspensions for multi-modal anti-glioma therapy via drug and antigen delivery

10.1186/s12951-021-01110-0 · 2021 · External reference

TAT and RVG Co-modified MSC-derived Exosomes-mediated Delivery of microRNA-15b-5p Inhibitor Alleviate Cerebral Ischemia and Reperfusion-induced Neuronal Apoptosis by Promoting HTR2C-ERK Signaling

10.1007/s12035-025-05249-x · 2025 · External reference

PepH3-modified nanocarriers for delivery of therapeutics across the blood-brain barrier

10.1186/s12987-025-00641-0 · 2025 · External reference

Assessing Mild Traumatic Brain Injury-Associated Blood-Brain Barrier (BBB) Damage and Restoration Using Late-Phase Perfusion Analysis by 3D ASL MRI: Implications for Predicting Progressive Brain Injury in a Focused Review

10.3390/ijms252111522 · 2024 · External reference

Fabrication of a phototheranostic nanoplatform for single laser-triggered NIR-II fluorescence imaging-guided photothermal/chemo/antiangiogenic combination therapy

10.1016/j.actbio.2022.08.013 · 2022 · External reference

Rhodiola crenulata alleviates hypobaric hypoxia-induced brain injury by maintaining BBB integrity and balancing energy metabolism dysfunction

10.1016/j.phymed.2024.155529 · 2024 · External reference

Evolution of blood-brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies

10.1016/j.apsb.2020.11.023 · 2021 · External reference

Targeting the Labile Iron Pool with Engineered DFO Nanosheets to Inhibit Ferroptosis for Parkinson's Disease Therapy

10.1002/adma.202409329 · 2024 · External reference

A nanoparticle-based wireless deep brain stimulation system that reverses Parkinson's disease

10.1126/sciadv.ado4927 · 2025 · External reference

A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics

10.3390/ijms23031851 · 2022 · External reference

Minocycline nanoplatform penetrates the BBB and enables the targeted treatment of Parkinson's disease with cognitive impairment

10.1016/j.jconrel.2024.11.066 · 2025 · External reference

Neuroprotective effects of intranasal extracellular vesicles from human platelet concentrates supernatants in traumatic brain injury and Parkinson's disease models

10.1186/s12929-024-01072-z · 2024 · External reference

Extracellular Vesicle-Mediated Delivery of Constrained Peptides Disrupts the Pathogenic Interaction of LRRK2-FADD in Parkinson's Disease

10.1002/jex2.70116 · 2026 · External reference

In vivo self-assembled siRNAs within small extracellular vesicles attenuate LRRK2-induced neurodegeneration in Parkinson's disease models

10.1016/j.jconrel.2024.12.045 · 2025 · External reference

Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins

10.1038/s41587-022-01456-2 · 2023 · External reference

Interfacing Nanomaterials with Biology through Ligand Engineering

10.1021/acs.accounts.3c00255 · 2023 · External reference

AI-Validated Brain Targeted mRNA Lipid Nanoparticles with Neuronal Tropism

10.1021/acsnano.4c15013 · 2025 · External reference

Targeting NMDA receptor signaling for therapeutic intervention in brain disorders

10.1515/revneuro-2022-0096 · 2023 · External reference

Viral Membrane Fusion: A Dance Between Proteins and Lipids

10.1146/annurev-virology-111821-093413 · 2023 · External reference

Lipid and Lipidation in Membrane Fusion

10.1007/s00232-022-00267-5 · 2022 · External reference

Cell Membrane-Coated Nanoparticles for Precision Medicine: A Comprehensive Review of Coating Techniques for Tissue-Specific Therapeutics

10.3390/ijms25042071 · 2024 · External reference

Iron ions-sequestrable and antioxidative carbon dot-based nano-formulation with nitric oxide release for Parkinson's disease treatment

10.1016/j.biomaterials.2024.122622 · 2024 · External reference

Extracellular Vesicles for the Diagnosis and Treatment of Parkinson's Disease

10.14336/ad.2021.0516 · 2021 · External reference

Emerging Nanotechnology for Treatment of Alzheimer's and Parkinson's Disease

10.3389/fbioe.2021.672594 · 2021 · External reference

Nanocarriers for Delivery of Oligonucleotides to the CNS

10.3390/ijms23020760 · 2022 · External reference

Exenatide-Modified Deferoxamine-Based Nanoparticles Ameliorates Neurological Deficits in Parkinson's Disease Mice

10.2147/ijn.s479670 · 2024 · External reference

Mitochondria-targeted nanoparticles in treatment of neurodegenerative diseases

10.1002/exp.20210115 · 2021 · External reference

Influence of charges deposited on membranes of human hyperdirect pathway axons on depolarization during subthalamic deep brain stimulation

10.1088/1741-2552/ace5de · 2023 · External reference

Novel Nose-to-brain delivery of carbenoxolone via mucoadhesive solid lipid nanoparticles for Parkinson's symptoms management: In vitro and in vivo evaluation in a rotenone-induced rat model

10.1016/j.ijpharm.2025.125197 · 2025 · External reference

Blood-brain barrier-penetrating single CRISPR-Cas9 nanocapsules for effective and safe glioblastoma gene therapy

10.1126/sciadv.abm8011 · 2022 · External reference

Parkin regulates microglial NLRP3 and represses neurodegeneration in Parkinson's disease

10.1111/acel.13834 · 2023 · External reference

The role of Toll-like receptors and neuroinflammation in Parkinson's disease

10.1186/s12974-022-02496-w · 2022 · External reference

Nonintuitive Immunogenicity and Plasticity of Alpha-Synuclein Conformers: A Paradigm for Smart Delivery of Neuro-Immunotherapeutics

10.3390/pharmaceutics16050609 · 2024 · External reference

Stimuli-responsive smart materials for biomedical applications

10.1016/j.mser.2025.101126 · 2026 · External reference

Neurotensin and Neurotensin Receptors in Stress-related Disorders: Pathophysiology & Novel Drug Targets

10.2174/1570159x21666230803101629 · 2024 · External reference

Nanotherapeutic Interventions for Parkinson's Disease: Modulating Pathogenic Mechanisms and Overcoming Therapeutic Obstacles

10.2147/ijn.s570452 · 2026 · External reference

Cell type-targeting nanoparticles in treating central nervous system diseases: Challenges and hopes

10.1515/ntrev-2023-0158 · 2023 · External reference

Blood–Brain Barrier: Structure, Function, Diseases, and Drug Delivery Systems

10.1002/mco2.70712 · 2026 · External reference

N-Methyl-D-Aspartate Receptors Mediate Synaptic Plasticity Impairment of Hippocampal Neurons Due to Arsenic Exposure

10.1016/j.neuroscience.2022.07.017 · 2022 · External reference

Brain-region-specific changes in neurons and glia and dysregulation of dopamine signaling in Grin2a mutant mice

10.1016/j.neuron.2023.08.004 · 2023 · External reference

Charge-Reversible Nanoparticles: Advanced Delivery Systems for Therapy and Diagnosis

10.1002/smll.202304713 · 2024 · External reference

Cancer cell-mitochondria hybrid membrane coated Gboxin loaded nanomedicines for glioblastoma treatment

10.1038/s41467-023-40280-3 · 2023 · External reference

Mitochondrial-targeted and ROS-responsive nanocarrier via nose-to-brain pathway for ischemic stroke treatment

10.1016/j.apsb.2023.06.011 · 2023 · External reference

Engineered MSC-EVs loaded with BDNF-enhancing neuropeptides via a non-disruptive method enhance post-stroke neuroregeneration via intranasal delivery

10.1186/s12951-025-03654-x · 2025 · External reference

Enhancement of Cognitive Function by Andrographolide-Loaded Lactose β-Cyclodextrin Nanoparticles: Synthesis, Optimization, and Behavioural Assessment

10.3390/ph17070966 · 2024 · External reference

Enhancing Intracellular Optical Performance and Stability of Engineered Nanomaterials via Aqueous Two-Phase Purification

10.1021/acs.nanolett.3c01727 · 2023 · External reference

Photoactive Nanomaterials for Wireless Neural Biomimetics, Stimulation, and Regeneration

10.1021/acsnano.2c08543 · 2022 · External reference

Harnessing two-dimensional nanomaterials for diagnosis and therapy in neurodegenerative diseases: Advances, challenges and prospects

10.1016/j.arr.2024.102205 · 2024 · External reference

Potential Biosafety of Mxenes: Stability, Biodegradability, Toxicity and Biocompatibility

10.1002/tcr.202300338 · 2024 · External reference

Biobased Polybutyrolactam Nanofiber with Excellent Biodegradability and Cell Growth for Sustainable Healthcare Textiles

10.1021/acs.biomac.4c00249 · 2024 · External reference

Targeted delivery of neural progenitor cell-derived extracellular vesicles for anti-inflammation after cerebral ischemia

10.7150/thno.56367 · 2021 · External reference

Mechanisms of immune response to inorganic nanoparticles and their degradation products

10.1016/j.addr.2021.114022 · 2022 · External reference

Copper-coordination driven brain-targeting nanoassembly for efficient glioblastoma multiforme immunotherapy by cuproptosis-mediated tumor immune microenvironment reprogramming

10.1186/s12951-024-03059-2 · 2024 · External reference

CAR-neutrophil mediated delivery of tumor-microenvironment responsive nanodrugs for glioblastoma chemo-immunotherapy

10.1038/s41467-023-37872-4 · 2023 · External reference

Nanomaterials for brain metastasis

10.1016/j.jconrel.2023.12.001 · 2024 · External reference

Peptide-Based Drug Delivery Systems

10.3390/medicina57111209 · 2021 · External reference

Brain Targeting Nanomedicines: Pitfalls and Promise

10.2147/ijn.s454553 · 2024 · External reference

Transforming the concept of connectivity: unveiling tunneling nanotube biology and their roles in brain development and neurodegeneration

10.1152/physrev.00023.2024 · 2025 · External reference

ROS-Drp1-mediated mitochondria fission contributes to hippocampal HT22 cell apoptosis induced by silver nanoparticles

10.1016/j.redox.2023.102739 · 2023 · External reference

Black Phosphorus Nanosheets Protect Neurons by Degrading Aggregative α-syn and Clearing ROS in Parkinson's Disease

10.1002/adma.202404576 · 2024 · External reference

Bioinspired Membrane-Based Cancer Vaccines for Immunotherapy: Progress and Perspectives

10.1002/smll.202412679 · 2025 · External reference

MXene-Based Nanomaterials for Bacterial Detection and Sonodynamic Sterilization

10.1002/smll.74682 · 2026 · External reference

Mastering Quality: Uniting Risk Assessment With Quality by Design (QbD) Principles for Pharmaceutical Excellence

10.7759/cureus.68215 · 2024 · External reference

Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset

10.1002/jps.23575 · 2013 · External reference

Novel single-domain antibodies targeting a unique transferrin receptor 1 epitope for cross-species delivery of drugs in the central nervous system

10.1016/j.jconrel.2025.114344 · 2025 · External reference

The Impact of the Blood-Brain Barrier and Its Dysfunction in Parkinson's Disease: Contributions to Pathogenesis and Progression

10.1021/acsomega.4c06546 · 2024 · External reference

Biomimetic nanodelivery system with simultaneous blood-brain barrier-crossing and neuroprotective abilities for anti-parkinsonian therapy

10.1186/s13020-025-01239-2 · 2025 · External reference

The Crucial Role of the Blood-Brain Barrier in Neurodegenerative Diseases: Mechanisms of Disruption and Therapeutic Implications

10.3390/jcm14020386 · 2025 · External reference

Receptor-mediated transcytosis of nanobodies targeting the heparin-binding EGF-like growth factor in human blood-brain barrier models

10.1016/j.jconrel.2025.113852 · 2025 · External reference

Abstract 2045: Novel TFRC humanized mouse model for drug delivery to the brain

10.1158/1538-7445.am2024-2045 · 2024 · External reference

Neurodegeneration models in Parkinson's disease: cellular and molecular paths to neuron death

10.1186/s12993-025-00279-w · 2025 · External reference

Single-cell RNA sequencing of CSF reveals neuroprotective RAC1(+) NK cells in Parkinson's disease

10.3389/fimmu.2022.992505 · 2022 · External reference

Brain drug delivery and neurodegenerative diseases: Polymeric PLGA-based nanoparticles as a forefront platform

10.1016/j.arr.2022.101658 · 2022 · External reference

Targeting CD47/SIRPα as a therapeutic strategy, where we are and where we are headed

10.1186/s40364-022-00373-5 · 2022 · External reference

Furan-Derived Lipid Nanoparticles for Transporting mRNA to the Central Nervous System

10.1021/jacs.4c16326 · 2025 · External reference

AI-enhanced virtual screening approach to hit identification for GluN1/GluN3A NMDA receptor

10.1038/s41401-025-01644-1 · 2026 · External reference

Neurotransmitter systems in the etiology of major neurological disorders: Emerging insights and therapeutic implications

10.1016/j.arr.2023.101994 · 2023 · External reference

Freestanding nanomaterials for subcellular neuronal interfaces

10.1016/j.isci.2021.103534 · 2022 · External reference

Nanomaterial technologies for precision diagnosis and treatment of brain hemorrhage

10.1016/j.biomaterials.2025.123269 · 2025 · External reference

Brain microenvironment-remodeling nanomedicine improves cerebral glucose metabolism, mitochondrial activity and synaptic function in a mouse model of Alzheimer's disease

10.1016/j.biomaterials.2025.123142 · 2025 · External reference

Monogenic Parkinson's Disease: Genotype, Phenotype, Pathophysiology, and Genetic Testing

10.3390/genes13030471 · 2022 · External reference

Single-cell transcriptomic and proteomic analysis of Parkinson's disease brains

10.1126/scitranslmed.abo1997 · 2024 · External reference

Large-scale proteomic analyses of incident Parkinson's disease reveal new pathophysiological insights and potential biomarkers

10.1038/s43587-025-00818-0 · 2025 · External reference

Reprogramming cancer therapeutics through artificial intelligence-guided drug repurposing: Computational innovation, experimental validation, and translational challenges

10.1016/j.ailsci.2026.100168 · 2026 · External reference

Unresolved reference

2025 · External reference

History of Traumatic Brain Injury Does Not Influence Rate of Progression of Clinical or Pathological Outcomes in Two Early Parkinson's Disease Cohorts

10.1111/ene.70090 · 2025 · External reference

Efficacy and Safety of Photobiomodulation Therapy for Motor Symptoms in Parkinson’s Disease: A Systematic Review and Meta-Analysis

10.3390/brainsci16090925 · 2026 · External reference

Effect on Dyskinesia of the Early Combination of Amantadine to Levodopa-Therapy in Parkinson's Disease: A Randomized, Placebo-Controlled Study (PREMANDYSK)

10.1002/mds.70120 · 2026 · External reference

Predictive value of cerebrospinal fluid Alzheimer’s disease biomarkers and neuropsychological measures for cognitive and motor outcomes in Parkinson’s disease

10.1093/braincomms/fcag166 · 2026 · External reference

Nanozyme-augmented clinical drug strategy for dopaminergic restoration and oxidative stress mitigation to rescue motor and cognitive deficits in Parkinson's disease

10.1016/j.biomaterials.2026.124391 · 2026 · External reference

Positron Emission Tomography Imaging in Clinical Trials for Parkinson's Disease: Applications of Metabolic Brain Network Approach

10.1002/mds.30231 · 2025 · External reference

Evolution of disease modifying therapy clinical trial design and therapeutic endpoints for Parkinson's disease

10.1177/1877718x261420002 · 2026 · External reference

Utility of Baseline Pathological, Neuroimaging and Clinical Markers for Prognosis in Early Parkinson's Disease

10.1177/08919887251397641 · 2026 · External reference

Nigrostriatal tau pathology in parkinsonism and Parkinson's disease

10.1093/brain/awad388 · 2024 · External reference

Progress towards therapies for disease modification in Parkinson's disease

10.1016/s1474-4422(21)00061-2 · 2021 · External reference

Treatment Options for Motor and Non-Motor Symptoms of Parkinson's Disease

10.3390/biom11040612 · 2021 · External reference

Clinical Safety and Legal Accountability of Artificial Intelligence in Hematology Diagnostic Laboratories: Risks, Failure Modes, Medicolegal Challenges, and Budgeting for Implementation

10.4103/joah.joah_33_26 · 2026 · External reference

The Yin and Yang of Microglia-Derived Extracellular Vesicles in CNS Injury and Diseases

10.3390/cells13221834 · 2024 · External reference